JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.